Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bruce E Johnson

Showing results (201-210 of 241) with videos related to

Pageof 25
Sort By:
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 6, 2007
Bronchioloalveolar carcinoma and lung adenocarcinoma: the clinical importance and research relevance of the 2004 World Health Organization pathologic criteriaWilliam D Travis, Kavita Garg, Wilbur A Franklin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 9, 2017
The Impact of Smoking and TP53 Mutations in Lung Adenocarcinoma Patients with Targetable Mutations-The Lung Cancer Mutation Consortium (LCMC2)Dara L Aisner, Lynette M Sholl, Lynne D Berry, et al.
JAMA|May 22, 2014
Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugsMark G Kris, Bruce E Johnson, Lynne D Berry, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 9, 2020
Genomic Characterization of <i>de novo</i> Metastatic Breast CancerAna C Garrido-Castro, Liam F Spurr, Melissa E Hughes, et al.
Nature Medicine|September 13, 2022
Neoadjuvant atezolizumab for resectable non-small cell lung cancer: an open-label, single-arm phase II trialJamie E Chaft, Filiz Oezkan, Mark G Kris, et al.
JCO Precision Oncology|November 29, 2022
Rare FGFR Oncogenic Alterations in Sequenced Pediatric Solid and Brain Tumors Suggest FGFR Is a Relevant Molecular Target in Childhood CancerLorena Lazo De La Vega, Hannah Comeau, Sarah Sallan, et al.
Nature Communications|February 18, 2016
Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpointsShohei Koyama, Esra A Akbay, Yvonne Y Li, et al.
Medrxiv : the Preprint Server for Health Sciences|June 5, 2026
Longitudinal multi-platform profiling reveals temporal dynamics of HER2, TROP2, PD-L1 and tumor-infiltrating lymphocytes in triple-negative breast cancerJorge Gomez Tejeda Zanudo, Busem Binboga Kurt, Allison Frangieh, et al.
Nature Cancer|October 7, 2025
A cellular and spatial atlas of TP53-associated tissue remodeling defines a multicellular tumor ecosystem in lung adenocarcinomaWilliam Zhao, Thinh T Nguyen, Atharva Bhagwat, et al.
JCO Precision Oncology|September 14, 2020
Identifying <i>ERBB2</i> Activating Mutations in HER2-Negative Breast Cancer: Clinical Impact of Institute-Wide Genomic Testing and Enrollment in Matched Therapy TrialsPedro Exman, Ana C Garrido-Castro, Melissa E Hughes, et al.
Pageof 25

Showing results (201-210 of 241) with videos related to

Sort By:
Pageof 25
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 6, 2007
Bronchioloalveolar carcinoma and lung adenocarcinoma: the clinical importance and research relevance of the 2004 World Health Organization pathologic criteriaWilliam D Travis, Kavita Garg, Wilbur A Franklin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 9, 2017
The Impact of Smoking and TP53 Mutations in Lung Adenocarcinoma Patients with Targetable Mutations-The Lung Cancer Mutation Consortium (LCMC2)Dara L Aisner, Lynette M Sholl, Lynne D Berry, et al.
JAMA|May 22, 2014
Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugsMark G Kris, Bruce E Johnson, Lynne D Berry, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 9, 2020
Genomic Characterization of <i>de novo</i> Metastatic Breast CancerAna C Garrido-Castro, Liam F Spurr, Melissa E Hughes, et al.
Nature Medicine|September 13, 2022
Neoadjuvant atezolizumab for resectable non-small cell lung cancer: an open-label, single-arm phase II trialJamie E Chaft, Filiz Oezkan, Mark G Kris, et al.
JCO Precision Oncology|November 29, 2022
Rare FGFR Oncogenic Alterations in Sequenced Pediatric Solid and Brain Tumors Suggest FGFR Is a Relevant Molecular Target in Childhood CancerLorena Lazo De La Vega, Hannah Comeau, Sarah Sallan, et al.
Nature Communications|February 18, 2016
Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpointsShohei Koyama, Esra A Akbay, Yvonne Y Li, et al.
Medrxiv : the Preprint Server for Health Sciences|June 5, 2026
Longitudinal multi-platform profiling reveals temporal dynamics of HER2, TROP2, PD-L1 and tumor-infiltrating lymphocytes in triple-negative breast cancerJorge Gomez Tejeda Zanudo, Busem Binboga Kurt, Allison Frangieh, et al.
Nature Cancer|October 7, 2025
A cellular and spatial atlas of TP53-associated tissue remodeling defines a multicellular tumor ecosystem in lung adenocarcinomaWilliam Zhao, Thinh T Nguyen, Atharva Bhagwat, et al.
JCO Precision Oncology|September 14, 2020
Identifying <i>ERBB2</i> Activating Mutations in HER2-Negative Breast Cancer: Clinical Impact of Institute-Wide Genomic Testing and Enrollment in Matched Therapy TrialsPedro Exman, Ana C Garrido-Castro, Melissa E Hughes, et al.
Pageof 25